Reference Detail

Ref Type

PMID

Authors

Vural Tagal, Shuguang Wei, Wei Zhang, Rolf A. Brekken, Bruce A. Posner, Adi F. Gazdar and Michael G. Roth

Title

Abstract LB-318: SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A-targeted therapies in non-small cell lung cancers (NSCLCs)

Journal	Vol	Issue	Date	Pages	Journal Short Title

URL

Abstract Text

Cancer Res July 15 2016 (76) (14 Supplement) LB-318

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
SMARCA4 loss	lung non-small cell carcinoma	sensitive	Tozasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines with SMARCA4 loss demonstrated increased sensitivity to Tozasertib (VX-680), compared to cell lines expressing wild-type SMARCA4, in culture (Cancer Res July 15 2016 (76) (14 Supplement) LB-318).	detail...
SMARCA4 mutant	lung non-small cell carcinoma	predicted - sensitive	Tozasertib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring a SMARCA4 mutation demonstrated sensitivity to Tozasertib (VX-680) in culture (Cancer Res July 15 2016 (76) (14 Supplement) LB-318).	detail...